期刊文献+

布地奈德混悬液联合肾上腺素雾化吸入治疗毛细支气管炎的疗效分析

The efficacy about budesonide combined use of epinephrine inhalation aerosol inhalation treatment of bronchiolitiS
下载PDF
导出
摘要 目的探讨布地奈德混悬液联合肾上腺素雾化吸入治疗毛细支气管炎的疗效及安全性。方法将128例毛细支气管炎患儿随机分为两组,均采用综合治疗,治疗组在常规抗感染、对瘫治疗的基础上予布地奈德混悬液与肾上腺素雾化吸入,疗程5~7d,对照组在常规抗感染、对症治疗的基础上,单用布地奈德混悬液雾化吸入,疗程7d。观察两组患儿症状、体征消失的时间、住院时间,并进行临床疗效分析。结果治疗组咳嗽、喘、憋症状缓解,呼吸困难好转,哮呜音、湿哕音消失时间,住院时间明显缩短,与对照组比较差异有统计学意义(P≤0.05)。结论布地奈德混悬液联合肾上腺素雾化吸入治疗毛细支气管炎,对急性期症状缓解优势明显,可缩短病程,减少住院时间,疗效肯定.使用安全。 Objective To investigate the efficacy and secure of budesonide combined with nebulized epinephrine inhalation in the treatment of capillary bronchiolitis. Methods One hundred and twenty - eight children with capillary bronchil- itis were randomly divided into tow groups. Both groups were given synthetical treatment. Treatment group received traditional therapy such as anti - influence and actcome, treatment additional budesonide and epinephrine inhalation aerosol inhalation, the period of treatment was 5 ~ 7 days. The control group received above and were treatment 7 days with budesonide only. The disappearance of the clinical symptoms and signs, during hospital stay were observed and clinical therapeutic effects in 2 groups were evaluated. Results The clinical with the symptoms including cough wheezing rale, difficulty breathing, pulmonary rales disappeared dry time and the hospital stay were significantly shortened. The prevalence rate in control group decreased significantly( P 〈 O. 05 ). Conclusion To reduce the acute symptoms of children with budesonide combined use of epineph- rine inhalation aerosol inhalation treatment of bronchiolitis the more obvious advantages. It could shorten the course of disease and hospital stay, achieve excellent efficacy, use safe.
出处 《中国医学创新》 CAS 2011年第33期26-27,共2页 Medical Innovation of China
关键词 毛细支气管炎 布地奈德混悬液 肾上腺素 治疗 Capillary bronehiolitis Budesonide Epinephrine Treatment
  • 相关文献

二级参考文献38

  • 1钱惠玲.布地奈德混悬液吸入治疗毛细支气管炎疗效观察[J].中国误诊学杂志,2004,4(9):1452-1453. 被引量:1
  • 2崔京浩,严轶东,郭建鹏,全姬善.布地奈德结肠靶向脉冲片的制备及体外释放度研究[J].解放军药学学报,2004,20(6):418-421. 被引量:7
  • 3余洁红.布地奈德雾化吸入治疗小儿急性喉炎[J].中国妇幼保健,2005,20(3):341-342. 被引量:10
  • 4韩诗淼,崔雁辉.支气管哮喘患者外周血单核细胞因子Th1/Th2失衡的检测[J].中国基层医药,2007,14(3):439-440. 被引量:32
  • 5陈素华,陈树全.儿科查房手册[M].南京.江苏科学技术出版社,1999:158.
  • 6Christensson C, Thoren A, Lindberg B. Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid- related adverse effects [ J ]. Drug Saf, 2008, 31 ( 11 ): 965 - 988.
  • 7Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonidc and oral prcdnisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2002, 165 (5) : 698 - 703.
  • 8Mirici A, Meral M, Akgun M. Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease[J]. Clin Drug Invest, 2003, 23 ( 1 ) : 55 - 62.
  • 9Selroos O, Edsbacker S, Hultquist C. Oncedaily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation [ J ]. J Asthma, 2004, 41 (8) : 771 - 790.
  • 10Vaghi A, Berg E, Liljedahl S, et al. In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomet hasone dipropionate (Clenil per Aerosol)[J]. Pulm Pharmacol Ther, 2005, 18(2): 151- 153.

共引文献123

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部